🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Lipella Pharmaceuticals announces board election and reverse stock split

Published 11/09/2024, 22:20
LIPO
-

Pittsburgh-based Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) reported on Wednesday the results of its Annual Meeting of Stockholders that took place on Monday. The meeting's outcomes included the election of its board of directors and the approval of a reverse stock split.


Seven director nominees were elected by the shareholders, including Jonathan Kaufman, Michael Chancellor, Lori Birder, Daniel Cohen, Byong (Christopher) Kim, Ryan Pruchnic, and Naoki Yoshimura.


Each will serve until the 2025 Annual Meeting of Stockholders. The number of votes withheld ranged from 30,427 to 69,981 for each candidate, while broker non-votes were 1,703,278 across the board.


Additionally, shareholders approved an amendment to the company's certificate of incorporation to effectuate a reverse stock split. The ratio will range from one-for-five to one-for-one hundred and fifty, at the discretion of the board of directors, to be executed within one year from the date of approval. The proposal received 3,881,533 votes for, 407,381 against, and 14,254 abstained.


The appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 4,232,289 votes for, 61,186 against, and 9,693 abstained.


In other recent news, Lipella Pharmaceuticals has faced a potential Nasdaq delisting due to an equity shortfall. The company's stockholders' equity fell below Nasdaq's minimum requirement, prompting a need for a compliance plan. Simultaneously, Lipella has initiated a Phase 2a clinical trial for LP-310, a potential treatment for Oral Lichen Planus, a chronic inflammatory condition affecting around 6 million Americans.


In addition, Lipella has announced plans for a registered direct offering of its common stock, aiming to raise approximately $1.28 million, with H.C. Wainwright & Co. serving as the exclusive placement agent.


The company has also set its 2024 annual meeting of stockholders, establishing deadlines for written submissions for proposals and nominations for director candidates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.